Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AMLN (DIABETES DRUGS) -- Ignore unavailable to you. Want to Upgrade?

To: Rudy Saucillo who wrote (1439)	7/31/1998 2:10:00 PM
From: wolfdog2	Read Replies (1) \| Respond to of 2173

Rudy, I think you are exagerating the negatives. Fact is that one P3 trial came a cropper. There were lots of large trials previous. All of them showed that the drug worked. The trial that failed had been poorly designed. For that you can blame the company. But I don't think it makes much sense to dismiss the Pramlintide based on one poorly designed trial. The private financing was absolutely necessary in order for AMLN to move forward. No one wants to negotiate with a large pharma while they are running out of cash. Thus, the cash not only will enable them to proceed with the trials, but to negotiate from a somewhat stronger position. If the future of Pramlintide were as negative as you make it, I doubt that anyone would have put good money into AMLIN at this point.